Correlation Between Valneva SE and Sonnet Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Valneva SE and Sonnet Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Valneva SE and Sonnet Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Valneva SE ADR and Sonnet Biotherapeutics Holdings, you can compare the effects of market volatilities on Valneva SE and Sonnet Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Valneva SE with a short position of Sonnet Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Valneva SE and Sonnet Biotherapeutics.

Diversification Opportunities for Valneva SE and Sonnet Biotherapeutics

0.66
  Correlation Coefficient

Poor diversification

The 3 months correlation between Valneva and Sonnet is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Valneva SE ADR and Sonnet Biotherapeutics Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonnet Biotherapeutics and Valneva SE is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Valneva SE ADR are associated (or correlated) with Sonnet Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonnet Biotherapeutics has no effect on the direction of Valneva SE i.e., Valneva SE and Sonnet Biotherapeutics go up and down completely randomly.

Pair Corralation between Valneva SE and Sonnet Biotherapeutics

Given the investment horizon of 90 days Valneva SE ADR is expected to generate 0.61 times more return on investment than Sonnet Biotherapeutics. However, Valneva SE ADR is 1.63 times less risky than Sonnet Biotherapeutics. It trades about -0.53 of its potential returns per unit of risk. Sonnet Biotherapeutics Holdings is currently generating about -0.52 per unit of risk. If you would invest  609.00  in Valneva SE ADR on August 27, 2024 and sell it today you would lose (166.00) from holding Valneva SE ADR or give up 27.26% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Valneva SE ADR  vs.  Sonnet Biotherapeutics Holding

 Performance 
       Timeline  
Valneva SE ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Valneva SE ADR has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Sonnet Biotherapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Valneva SE and Sonnet Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Valneva SE and Sonnet Biotherapeutics

The main advantage of trading using opposite Valneva SE and Sonnet Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Valneva SE position performs unexpectedly, Sonnet Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will offset losses from the drop in Sonnet Biotherapeutics' long position.
The idea behind Valneva SE ADR and Sonnet Biotherapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance